Becton, Dickinson and Company BDX NYSE

Becton, Dickinson and Company (BDX) reported total assets of $55.33B and total liabilities of $29.94B for fiscal year 2025, resulting in total equity of $25.39B.

The company held $859M in cash and short-term investments. Total debt stood at $19.18B, with net debt of $18.33B. The Debt-to-Equity (D/E) ratio was 0.76 (moderate).

Current ratio is 1.11, suggesting adequate short-term liquidity. Interest coverage is 4.2x (adequate).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (73/100) — Total assets $55.33B and equity $25.39B support the company's competitive scale
• VALUE (36/100) — Debt-to-Equity 0.76 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

ARGX

argenx SE

$828.35

+2.36%

CAH

Cardinal Health, Inc.

$214.95

+0.36%

IDXX

IDEXX Laboratories, Inc.

$584.05

+1.75%

EW

Edwards Lifesciences Corporation

$78.20

+0.10%

HLN

Haleon plc

$9.70

-1.32%

ALC

Alcon Inc.

$79.94

+0.25%

A

Agilent Technologies, Inc.

$120.40

+2.47%

RMD

ResMed Inc.

$230.69

+0.19%